Anders Nykjaer
Gründer bei Insusense ApS
Aktive Positionen von Anders Nykjaer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Aarhus | Corporate Officer/Principal | - | - |
Insusense ApS
Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Gründer | - | - |
Karriereverlauf von Anders Nykjaer
Ehemalige bekannte Positionen von Anders Nykjaer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 | 23.03.2010 |
Gründer | 02.09.2009 | 23.03.2010 | |
Lundbeck Foundation
Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Vorsitzender | 02.09.2009 | - |
Ausbildung von Anders Nykjaer
University of Aarhus | Doctorate Degree |
Statistik
International
Dänemark | 5 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Doctorate Degree | 2 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | Health Technology |
Lundbeck Foundation
Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Miscellaneous |
Insusense ApS
Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Börse
- Insiders
- Anders Nykjaer
- Erfahrung